These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 37922771

  • 1. A novel intergenic (between REG3A and CTNNA2-AS1)-ALK fusion responds to alectinib in lung adenocarcinoma.
    Liu Z, Wu Q, Li W, Li P, Huang L, Wang T, Zhou Q.
    Lung Cancer; 2023 Dec; 186():107386. PubMed ID: 37922771
    [Abstract] [Full Text] [Related]

  • 2. A novel alectinib-sensitive CTNND1-ALK fusion in a lung adenocarcinoma patient: a case report.
    Tian X, Liao Q, Yang Q, Chen L, Xiao M, Cheng Y.
    Invest New Drugs; 2022 Aug; 40(4):850-853. PubMed ID: 35441911
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Dramatic response to alectinib in a lung adenocarcinoma patient harboring a Novel SSFA2-ALK fusion.
    Lin X, Yang X, Tan Y, Duan Q, He M.
    Invest New Drugs; 2022 Oct; 40(5):1160-1163. PubMed ID: 35608716
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A novel intergenic region (chr2: 30,193,816)-ALK fusion shows sensitivity to Alectinib in lung adenocarcinoma.
    Wang T, Du G, Niu M, Liu R.
    BMC Pulm Med; 2023 Feb 08; 23(1):60. PubMed ID: 36755262
    [Abstract] [Full Text] [Related]

  • 13. Excellent response of lung adenocarcinoma harboring a rare SLC8A1 downstream intergenic region ALK fusion to ceritinib treatment: A case report.
    Fang L, Ding G, Wang M, Ye Y, Yan X, Ding P, Wang J, Zhang Y.
    Medicine (Baltimore); 2022 Aug 26; 101(34):e30255. PubMed ID: 36042596
    [Abstract] [Full Text] [Related]

  • 14. Identification of a EML4-ALK exon 19 fusion variant in lung adenocarcinoma and alectinib resistance.
    Liu D, Xu X, Wen J, Zhang C, Fan M.
    Lung Cancer; 2021 Oct 26; 160():32-35. PubMed ID: 34391065
    [Abstract] [Full Text] [Related]

  • 15. Lung adenocarcinoma with a novel SRBD1-ALK Fusion responding to crizotinib.
    Chen Y, Zhang X, Jiang Q, Wang B, Wang Y, Junrong Y.
    Lung Cancer; 2020 Aug 26; 146():370-372. PubMed ID: 32527613
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.